Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer

Lancet Oncol. 2023 Jun;24(6):589-593. doi: 10.1016/S1470-2045(23)00165-1. Epub 2023 May 2.
No abstract available

MeSH terms

  • Aminopyridines / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Benzimidazoles / adverse effects
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Receptor, ErbB-2

Substances

  • abemaciclib
  • Aminopyridines
  • Benzimidazoles
  • Receptor, ErbB-2